【第24回】血液がん知っとかナイト「慢性骨髄性白血病」

[24th] Blood Cancer Knowledge Night "Chronic Myeloid Leukemia" Medical Advances Bring About a New Stage of Treatment CML is a disease caused by abnormalities in hematopoietic stem cells, rooted in the occurrence of specific genetic abnormalities. The development of tyrosine kinase inhibitors (TKIs) that target these abnormalities has dramatically improved treatment outcomes. Furthermore, the current treatment goal is to achieve and maintain deep molecular remission and achieve treatment-free remission, which prevents relapse even after treatment cessation. This lecture will outline the evolution of CML treatment and new treatment stages. Date: Tuesday, February 10, 2026 Lecturer: Dr. Norio Iriyama Chief, Department of Hematology and Rheumatology, Saitama Hospital, National Hospital Organization Graduated from Nihon University in 1998. He is a hematologist who has devoted himself to clinical training and has conducted numerous basic and clinical research projects. He has participated in clinical research groups such as the Japan Association of Clinical Oncology Scientists (JALSG), the Kanto CML Study Group, the CML-CSG, the J-CHARGE Study Group, and the Malignant Lymphoma Treatment Study Group, generating a wealth of evidence. For more information, go to: https://www.bloodcancerforum.jp/night... Organized by: Certified NPO CancerNet Japan Please subscribe to our channel: https://goo.gl/GEVk4j Please check the publication date listed on each page. The medical information contained in this content is general and may not apply to everyone. Please consult your doctor regarding treatment options and methods.